ANDA 91619, held by Sigmapharm Labs LLC. Disulfiram.
As of Nov 16, 2026, ANDA 91619 (Disulfiram), held by Sigmapharm Labs LLC, was first approved by FDA on Mar 28, 2011, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE: Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. Disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2011 | Original application | Approved |
| Disulfiram250MG · tablet;oral | Disulfiram | Rx |
| Disulfiram500MG · tablet;oral | Disulfiram | Rx |
| Dec 6, 2016 | Supplement 4Manufacturing | Approved | None posted |
| Mar 28, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters